NTRP - ニュ―ロトロ―プ (Neurotrope Inc.)

NTRPのニュース

   Insider Buying: Neurotrope Inc (NASDAQ:NTRP) Director Acquires $53,500.00 in Stock  2020/10/22 05:08:50 Stock Observer
Neurotrope Inc (NASDAQ:NTRP) Director Joshua Silverman bought 50,000 shares of Neurotrope stock in a transaction dated Thursday, October 15th. The shares were bought at an average cost of $1.07 per share, with a total value of $53,500.00. Following the completion of the acquisition, the director now owns 50,000 shares of the company’s stock, valued at […]
   Neurotrope Inc (NASDAQ:NTRP) Director Acquires $53,500.00 in Stock  2020/10/21 08:38:42 Dakota Financial News
Neurotrope Inc (NASDAQ:NTRP) Director Joshua Silverman bought 50,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was purchased at an average cost of $1.07 per share, with a total value of $53,500.00. Following the completion of the purchase, the director now directly owns 50,000 shares in the company, valued at […]
   BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1  2020/06/10 12:00:00 Business Wire
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1
   Neurotrope : Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease | MarketScreener  2020/05/28 13:56:12 MarketScreener
- New Phase 2 Study to Be Conducted in Collaboration with NIHUnder a $2.7 Million Grant- -Management to Host Investor Conference Call and Webcast Today at 11:00… | May 28, 2020
   Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding  2020/01/22 16:14:15 Benzinga
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on Benzinga.com
   Insider Buying: Neurotrope Inc (NASDAQ:NTRP) Director Acquires $53,500.00 in Stock  2020/10/22 05:08:50 Stock Observer
Neurotrope Inc (NASDAQ:NTRP) Director Joshua Silverman bought 50,000 shares of Neurotrope stock in a transaction dated Thursday, October 15th. The shares were bought at an average cost of $1.07 per share, with a total value of $53,500.00. Following the completion of the acquisition, the director now owns 50,000 shares of the company’s stock, valued at […]
   Neurotrope Inc (NASDAQ:NTRP) Director Acquires $53,500.00 in Stock  2020/10/21 08:38:42 Dakota Financial News
Neurotrope Inc (NASDAQ:NTRP) Director Joshua Silverman bought 50,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was purchased at an average cost of $1.07 per share, with a total value of $53,500.00. Following the completion of the purchase, the director now directly owns 50,000 shares in the company, valued at […]
   BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1  2020/06/10 12:00:00 Business Wire
DANVILLE, Calif.--(BUSINESS WIRE)--BryoLogyx announces agreements with Neurotrope to acquire bryostatin-1 immuno-oncology data package and supply synthetic bryostatin-1
   Neurotrope : Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease | MarketScreener  2020/05/28 13:56:12 MarketScreener
- New Phase 2 Study to Be Conducted in Collaboration with NIHUnder a $2.7 Million Grant- -Management to Host Investor Conference Call and Webcast Today at 11:00… | May 28, 2020
   Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding  2020/01/22 16:14:15 Benzinga
Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP ) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "203 study" that evaluated its experimental Alzheimer's disease candidate Bryostatin-1 , Neurotrope said the data showed improvement in cognitive function of pre-specified Moderate Stratum patients at week 13, which is the primary endpoint. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment," said Dr. Marwan Sabbagh, who helped design the trial … Full story available on Benzinga.com

calendar